Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
β-Lactamases are enzymes produced by bacteria to inactivate β-lactam antibiotics by hydrolyzing the β-lactam ring, thus conferring resistance. The Ambler molecular classification groups them into four classes (A, B, C, D); Class A, C, and D β-lactamases are serine hydrolases that use a serine residue at the active site to hydrolyze their substrates, while class B comprises metallo-β-lactamases requiring zinc, and is not included here. Class A includes enzymes such as TEM, SHV, CTX-M, KPC; class C includes AmpC-type enzymes; and class D includes OXA-type enzymes, with each class associated with varying substrate profiles and resistance patterns. These enzymes play a major role in clinical antibiotic resistance, particularly to penicillins, cephalosporins, and carbapenems, posing a significant threat to the efficacy of current antibiotic therapies.
Catalytic hydrolysis of the beta-lactam ring in antibiotics, rendering the drugs inactive. This involves covalent acyl-enzyme intermediate formation via serine hydrolysis at the active site. Resistance is thereby provided against broad-spectrum beta-lactams through this enzymatic inactivation.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on β-Lactamase (Class A, C, and D).